Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 21;10:1211. doi: 10.3389/fimmu.2019.01211

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Costa-Rocha, Campi-Azevedo, Peruhype-Magalhães, Coelho-dos-Reis, Fradico, Souza-Lopes, Reis, Freire, Costa-Pereira, Mambrini, Maia, Lima, Noronha, Xavier, Camacho, Albuquerque, Farias, Castro, Homma, Romano, Domingues, Martins, Teixeira-Carvalho and Martins-Filho.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Study design flowchart. The consort diagram summarizes the study steps. This is a 8-years follow-up study, of adult male army conscripts from Rio de Janeiro, average age of 19.4 years old, who had received the reference full dose and subdoses of 17DD-YF vaccine during the dose-response study in 2009 (12). From the eligible population (n = 319), only 98 volunteers agreed to provide two blood samples, one without anticoagulant for humoral analysis and an additional heparinized sample for cellular immunity assays. These volunteers were categorized into six groups, according to the dose of 17DD-YF vaccine administered in 2009: 27,476IU, considered the reference dose (, n = 16); 10,447IU (, n = 17); 3,013IU (, n = 19); 587IU (, n = 17); 158IU (, n = 18), and 31IU (, n = 11). An additional group of non-vaccinated adult male army conscripts, referred as NV(day0), was included as a control (□, n = 46). Humoral and cellular immunity profile was determined for each volunteer using the YF-plaque reduction neutralization test (PRNT) and in vitro YF-specific phenotypic & functional biomarkers.

Inline graphic — Study design flowchart. The consort diagram summarizes the study steps. This is a 8-years follow-up study, of adult male army conscripts from Rio de Janeiro, average age of 19.4 years old, who had received the reference full dose and subdoses of 17DD-YF vaccine during the dose-response study in 2009 (12). From the eligible population (n = 319), only 98 volunteers agreed to provide two blood samples, one without anticoagulant for humoral analysis and an additional heparinized sample for cellular immunity assays. These volunteers were categorized into six groups, according to the dose of 17DD-YF vaccine administered in 2009: 27,476IU, considered the reference dose (, n = 16); 10,447IU (, n = 17); 3,013IU (, n = 19); 587IU (, n = 17); 158IU (, n = 18), and 31IU (, n = 11). An additional group of non-vaccinated adult male army conscripts, referred as NV(day0), was included as a control (□, n = 46). Humoral and cellular immunity profile was determined for each volunteer using the YF-plaque reduction neutralization test (PRNT) and in vitro YF-specific phenotypic & functional biomarkers.